Fernando Munguia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fernando Munguia has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Alan Bonder
Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
3 shared publications - Natalia Rojas Amaris
Division of Gastroenterology, Hepatology, and Nutrition, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
3 shared publications - Ana Marenco-Flores
Division of Gastroenterology, Hepatology, and Nutrition, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
2 shared publications - Behnam Saberi
Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
2 shared publications - Daniela Goyes
Division of Digestive Diseases, Yale School of Medicine, New Haven, CT 06520, USA
2 shared publications - Victoria Abadi-Ron
Division of Gastroenterology, Hepatology, and Nutrition, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA
2 shared publications
Latest Publications
- Open Access
- 16 October 2026
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
Immunoglobulin G and liver stiffness in autoimmune hepatitis: Timing matters more than biochemical correction
Objectives: Transient elastography may overestimate fibrosis in autoimmune hepatitis (AIH) because hepatic inflammation independently increases liver stiffness measurement (LSM). We aimed to determine which inflammation markers confound LSM in AIH, whether algebraic correction improves accuracy, and when LSM becomes reliable for fibrosis staging. Methods: Single-center retrospective cohort of adults with AIH, paired diagnostic Metavir biopsy, and at least one FibroScan visit with same-visit alanine aminotransferase (ALT) and immunoglobulin G (IgG). Mixed-effects linear regression modeled LSM on biopsy stage, ALT, IgG, and time since diagnosis with a patient-level random intercept. An inflammation-adjusted LSM was computed by subtracting estimated ALT and IgG contributions. Spearman correlation and DeLong-tested AUROC for advanced fibrosis (F3–F4) compared measured and adjusted LSM, stratified by inflammation state and treatment timing. Results: We analyzed 208 FibroScan observations from 119 AIH patients (49 with advanced fibrosis). IgG was independently associated with LSM (β = +0.003 kPa per mg/dL, p < 0.001) while ALT was not (β ≈ 0, p = 0.68). The IgG–LSM relationship varied by treatment timing (IgG × 0–6 months interaction p = 0.001; IgG × 12–24 months p = 0.004). Algebraic correction did not improve discrimination (full-cohort AUROC measured 0.76 vs adjusted 0.72, DeLong p = 0.18). LSM accuracy for advanced fibrosis varied by timing: AUROC 0.71 pretreatment (n = 35), 0.64 at 12–24 months (n = 22), and 0.83 beyond 24 months (n = 72). Conclusions: In AIH, IgG—not ALT—independently inflates LSM, with a time-dependent effect strongest early after diagnosis. Algebraic correction did not improve fibrosis discrimination, but LSM accuracy improved substantially beyond 24 months after AIH diagnosis. Timing rather than algebraic correction is the more actionable clinical strategy for FibroScan interpretation in AIH.
- 16 October 2026
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
Open AccessImmunoglobulin G and liver stiffness in autoimmune hepatitis: Timing matters more than biochemical correction
Objectives: Transient elastography may overestimate fibrosis in autoimmune hepatitis (AIH) because hepatic inflammation independently increases liver stiffness measurement (LSM). We aimed to determine which inflammation markers confound LSM in AIH, whether algebraic correction improves accuracy, and when LSM becomes reliable for fibrosis staging. Methods: Single-center retrospective cohort of adults with AIH, paired diagnostic Metavir biopsy, and at least one FibroScan visit with same-visit alanine aminotransferase (ALT) and immunoglobulin G (IgG). Mixed-effects linear regression modeled LSM on biopsy stage, ALT, IgG, and time since diagnosis with a patient-level random intercept. An inflammation-adjusted LSM was computed by subtracting estimated ALT and IgG contributions. Spearman correlation and DeLong-tested AUROC for advanced fibrosis (F3–F4) compared measured and adjusted LSM, stratified by inflammation state and treatment timing. Results: We analyzed 208 FibroScan observations from 119 AIH patients (49 with advanced fibrosis). IgG was independently associated with LSM (β = +0.003 kPa per mg/dL, p < 0.001) while ALT was not (β ≈ 0, p = 0.68). The IgG–LSM relationship varied by treatment timing (IgG × 0–6 months interaction p = 0.001; IgG × 12–24 months p = 0.004). Algebraic correction did not improve discrimination (full-cohort AUROC measured 0.76 vs adjusted 0.72, DeLong p = 0.18). LSM accuracy for advanced fibrosis varied by timing: AUROC 0.71 pretreatment (n = 35), 0.64 at 12–24 months (n = 22), and 0.83 beyond 24 months (n = 72). Conclusions: In AIH, IgG—not ALT—independently inflates LSM, with a time-dependent effect strongest early after diagnosis. Algebraic correction did not improve fibrosis discrimination, but LSM accuracy improved substantially beyond 24 months after AIH diagnosis. Timing rather than algebraic correction is the more actionable clinical strategy for FibroScan interpretation in AIH.
- Open Access
- 14 October 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (20) , 7928
Liver Stiffness, Patient-Reported Fatigue, and Pruritus in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: A Cross-Sectional Study
Background: Fatigue and pruritus are common and disabling in primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), but their severity is not reliably explained by standard biochemical markers. Whether liver stiffness measured by transient elastography reflects these symptoms remains unclear. This study examined associations between liver stiffness and fatigue and pruritus in PBC and PSC, and between routine biochemical measures and symptom burden. Methods: This cross-sectional analysis included 107 patients (56 PBC, 51 PSC) from a prospective autoimmune liver disease registry. Fatigue was assessed with the CLDQ-29 fatigue domain and pruritus with the CLDQ-29 pruritus item or the itch visual analog scale. Multivariable linear and ordered logistic regression examined associations between liver stiffness and fatigue and pruritus, adjusted for disease type, age, and sex. Spearman correlations assessed associations between liver stiffness and clinical and laboratory variables, with Benjamini–Hochberg correction. Receiver operating characteristic analysis assessed discrimination. Results: Patients with PBC were older (59 vs. 51 years; p < 0.001) and more often female (96.4% vs. 56.9%; p < 0.001) than those with PSC. Liver stiffness (6.0 vs. 6.8 kPa; p = 0.101), fatigue scores, pruritus scores, and itch VAS were similar between groups. Liver stiffness was not associated with fatigue (β = 0.005; p = 0.835) or pruritus (OR = 0.97; p = 0.190) after adjustment; only age was associated with fatigue (β = 0.021; p = 0.020). Among laboratory measures, only ALP remained correlated with liver stiffness after correction (ρ = 0.309; adjusted p = 0.027). In PSC alone, higher liver stiffness was associated with worse pruritus (ρ = −0.37; p = 0.009), a finding not seen in PBC. Liver stiffness alone showed limited discrimination for fatigue (AUC 0.46) and pruritus (AUC 0.56); a model with disease type, age, and sex improved discrimination modestly for fatigue (AUC 0.60) but not for pruritus (AUC 0.57). Conclusions: Liver stiffness was not associated with fatigue or pruritus in the overall cohort of patients with PBC and PSC, and a possible association with pruritus in PSC needs confirmation. Patient-reported outcomes should be assessed alongside biochemical and elastographic measures, and how they relate to objective measures of disease remains an open question.
- 14 October 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (20) , 7928
Open AccessLiver Stiffness, Patient-Reported Fatigue, and Pruritus in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: A Cross-Sectional Study
Background: Fatigue and pruritus are common and disabling in primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), but their severity is not reliably explained by standard biochemical markers. Whether liver stiffness measured by transient elastography reflects these symptoms remains unclear. This study examined associations between liver stiffness and fatigue and pruritus in PBC and PSC, and between routine biochemical measures and symptom burden. Methods: This cross-sectional analysis included 107 patients (56 PBC, 51 PSC) from a prospective autoimmune liver disease registry. Fatigue was assessed with the CLDQ-29 fatigue domain and pruritus with the CLDQ-29 pruritus item or the itch visual analog scale. Multivariable linear and ordered logistic regression examined associations between liver stiffness and fatigue and pruritus, adjusted for disease type, age, and sex. Spearman correlations assessed associations between liver stiffness and clinical and laboratory variables, with Benjamini–Hochberg correction. Receiver operating characteristic analysis assessed discrimination. Results: Patients with PBC were older (59 vs. 51 years; p < 0.001) and more often female (96.4% vs. 56.9%; p < 0.001) than those with PSC. Liver stiffness (6.0 vs. 6.8 kPa; p = 0.101), fatigue scores, pruritus scores, and itch VAS were similar between groups. Liver stiffness was not associated with fatigue (β = 0.005; p = 0.835) or pruritus (OR = 0.97; p = 0.190) after adjustment; only age was associated with fatigue (β = 0.021; p = 0.020). Among laboratory measures, only ALP remained correlated with liver stiffness after correction (ρ = 0.309; adjusted p = 0.027). In PSC alone, higher liver stiffness was associated with worse pruritus (ρ = −0.37; p = 0.009), a finding not seen in PBC. Liver stiffness alone showed limited discrimination for fatigue (AUC 0.46) and pruritus (AUC 0.56); a model with disease type, age, and sex improved discrimination modestly for fatigue (AUC 0.60) but not for pruritus (AUC 0.57). Conclusions: Liver stiffness was not associated with fatigue or pruritus in the overall cohort of patients with PBC and PSC, and a possible association with pruritus in PSC needs confirmation. Patient-reported outcomes should be assessed alongside biochemical and elastographic measures, and how they relate to objective measures of disease remains an open question.
- Open Access
Nanotechnology-Driven Epigenetic Targeting: Tailoring Ovarian Cancer Therapeutics
Epigenetic mechanisms play a crucial role in OC drug resistance, and emerging evidence suggests that dysregulated epigenetic modifications are among the key contributors to OC. Epigenetic agents, including DNA methyltransferase inhibitors, histone deacetylase inhibitors, and non-coding RNA-based therapeutics, have important limitations, including poor water solubility, limited tissue distribution, low stability, and systemic toxicity. To overcome this, a novel drug delivery system is needed to manage variability in drug administration and maximize the efficacy of these drugs. In this regard, nanotechnology offers an attractive option for formulating epigenetic drugs with various encapsulation strategies to increase bioavailability and drug efficacy, reduce drug dose, administration frequency, and toxicity, and enhance cellular internalization and tumor-targeted delivery. In this review, we summarize various epigenetic regulators and their roles in OC therapy resistance as well as the development of nanosystems for epigenetic drug delivery, which could lay the foundation for designing nanoformulations encapsulating epigenetic therapeutics, ultimately advancing personalized, targeted therapy for patients with OC. This review also discusses the current clinical status of nanocarrier platforms and translational barriers that limit the clinical development of epigenetic nanomedicine, highlighting the future directions required for successful clinical translation.
Open AccessNanotechnology-Driven Epigenetic Targeting: Tailoring Ovarian Cancer Therapeutics
Epigenetic mechanisms play a crucial role in OC drug resistance, and emerging evidence suggests that dysregulated epigenetic modifications are among the key contributors to OC. Epigenetic agents, including DNA methyltransferase inhibitors, histone deacetylase inhibitors, and non-coding RNA-based therapeutics, have important limitations, including poor water solubility, limited tissue distribution, low stability, and systemic toxicity. To overcome this, a novel drug delivery system is needed to manage variability in drug administration and maximize the efficacy of these drugs. In this regard, nanotechnology offers an attractive option for formulating epigenetic drugs with various encapsulation strategies to increase bioavailability and drug efficacy, reduce drug dose, administration frequency, and toxicity, and enhance cellular internalization and tumor-targeted delivery. In this review, we summarize various epigenetic regulators and their roles in OC therapy resistance as well as the development of nanosystems for epigenetic drug delivery, which could lay the foundation for designing nanoformulations encapsulating epigenetic therapeutics, ultimately advancing personalized, targeted therapy for patients with OC. This review also discusses the current clinical status of nanocarrier platforms and translational barriers that limit the clinical development of epigenetic nanomedicine, highlighting the future directions required for successful clinical translation.
- Open Access
- 19 June 2026
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
Current Treatment of Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: A Comprehensive Review
Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are chronic cholestatic liver diseases characterized by bile duct injury that may progress to fibrosis, cirrhosis, liver failure, and malignancy and ultimately require liver transplantation. Although these diseases share several clinical features, they differ substantially in pathogenesis, clinical course, and therapeutic approaches. Ursodeoxycholic acid remains the standard first-line therapy for PBC; patients with an inadequate biochemical response may be treated with second-line agents such as seladelpar, elafibranor, or fibrates. In contrast, no approved therapy has been shown to slow disease progression in PSC. Emerging therapies primarily target symptom and complication management, and overall management focuses on surveillance and timely referral for liver transplantation. This review summarizes current approaches to risk assessment, treatment, symptom management, monitoring, and transplantation decision-making in both conditions. Cite this article as: Abadi-Ron V, Marenco-Flores A, Rojas-Amaris N, et al. Current treatment of primary biliary cholangitis and primary sclerosing cholangitis: A comprehensive review. Turk J Gastroenterol. Published online June 19, 2026. doi: 10.5152/tjg.2026.26267
- 19 June 2026
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
Open AccessCurrent Treatment of Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: A Comprehensive Review
Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are chronic cholestatic liver diseases characterized by bile duct injury that may progress to fibrosis, cirrhosis, liver failure, and malignancy and ultimately require liver transplantation. Although these diseases share several clinical features, they differ substantially in pathogenesis, clinical course, and therapeutic approaches. Ursodeoxycholic acid remains the standard first-line therapy for PBC; patients with an inadequate biochemical response may be treated with second-line agents such as seladelpar, elafibranor, or fibrates. In contrast, no approved therapy has been shown to slow disease progression in PSC. Emerging therapies primarily target symptom and complication management, and overall management focuses on surveillance and timely referral for liver transplantation. This review summarizes current approaches to risk assessment, treatment, symptom management, monitoring, and transplantation decision-making in both conditions. Cite this article as: Abadi-Ron V, Marenco-Flores A, Rojas-Amaris N, et al. Current treatment of primary biliary cholangitis and primary sclerosing cholangitis: A comprehensive review. Turk J Gastroenterol. Published online June 19, 2026. doi: 10.5152/tjg.2026.26267